Every 10-Q that 60 Degrees Pharmaceuticals, Inc. Warrant (SXTPW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SXTPW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTPW filings page.
60 Degrees Pharmaceuticals, Inc. reported that for the six months ended June 30, 2026, net revenue was $133,175, down from $440,831 a year earlier as prior-period research revenue did not recur, while net product revenue increased. Operating expenses rose to $4,499,238, leading to a net loss attributable to the company of $4,353,740 and a net loss attributable to common stockholders of $4,604,865. Net cash used in operating activities was $4,973,280.
Cash and cash equivalents were $1,022,606 and total assets $4,282,694 at June 30, 2026. Management states there is substantial doubt about the company’s ability to continue as a going concern for one year from issuance, even after raising approximately $3.37 million through at-the-market offerings in early 2026 and disclosing an additional ~$0.7 million in net proceeds from a July 2026 PIPE offering. The company also carries a Level 3 derivative liability of $384,973 tied to a potential $10 million milestone payment to Knight Therapeutics and has significant customer concentration, with a small number of distributors accounting for most receivables and product revenues.
60 Degrees Pharmaceuticals, Inc. reported a net loss attributable to common stockholders of $2.21 million for the quarter ended March 31, 2026, compared with $2.00 million a year earlier. Net product revenue was $162,092, essentially flat versus $163,552 in 2025, while prior-year research revenue of $92,731 did not recur.
Operating expenses rose slightly to $2.17 million, driven mainly by general and administrative costs of $1.89 million, with research and development at $281,464. Cash used in operating activities was $2.74 million, but the company boosted liquidity through at-the-market equity sales, ending the quarter with cash and cash equivalents of $3.34 million.
Management discloses an accumulated deficit of $49.98 million and explicitly states that recurring losses, limited cash runway and funding needs raise substantial doubt about the company’s ability to continue as a going concern for one year from the issuance of these financial statements.
60 Degrees Pharmaceuticals is a specialty pharmaceutical company marketing the FDA-approved malaria prevention product Arakoda and developing additional tafenoquine-based and other programs. For the three months ended June 30, 2025 the company reported net revenue of $257,820 (including $100,932 product revenue and $206,939 research revenue) and a gross profit of $50,881. Cash and cash equivalents were $1,966,930 at June 30, 2025, up from $1,659,353 at December 31, 2024, aided by net financing proceeds of approximately $1.7 million from January and February 2025 registered offerings.
Despite the revenue increase, the company reported a six-month net loss of $3,612,231, used $3,047,494 in operating activities during the six months, and had an accumulated deficit of $44,138,232. Derivative liabilities tied to a contingent milestone (Knight) were $776,172. Management states there is substantial doubt about the company’s ability to continue as a going concern without raising additional capital. The company also faces customer concentration (significant customers comprised ~99% of product revenue for the quarter) and sole-vendor API supply risk.